# Maricopa Integrated Health Systems Formulary Prior Auth Criteria

**Drug: Gleevec** (Imatinib)

## Therapy:

Is indicated for the treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase or in chronic phase after failure of interferon-alpha therapy Effectiveness is based on overall hematologic and cytogenetic response rates.

### **Inclusions:**

- **A)** What phase is the patient in
  - 1) Blastic
  - 2) Myeloid blast crisis
  - 3) Accelerated phase
  - 4) Chronic phase
- **B)** Failure of interferon-alpha therapy (e.g. Intron-A, Roferon-A)
- C) Is (or was) the patient taking hydroxyurea or busulfan
- **D)** Request comes from Oncology

### **Risk Factor/Contraindications**

Pregnancy category D- women of childbearing potential should be advised to avoid becoming pregnant

#### **Authorization:**

Initially six months with reauthorization of six months with documented efficacy

<b>Medical Director</b>	
Date	